NL1024831A1 - N-terminaal monogepegyleerde conjugaten van humaan groeihormoon en werkwijze voor de bereiding daarvan. - Google Patents

N-terminaal monogepegyleerde conjugaten van humaan groeihormoon en werkwijze voor de bereiding daarvan.

Info

Publication number
NL1024831A1
NL1024831A1 NL1024831A NL1024831A NL1024831A1 NL 1024831 A1 NL1024831 A1 NL 1024831A1 NL 1024831 A NL1024831 A NL 1024831A NL 1024831 A NL1024831 A NL 1024831A NL 1024831 A1 NL1024831 A1 NL 1024831A1
Authority
NL
Netherlands
Prior art keywords
preparation
growth hormone
human growth
pegylated human
terminal mono
Prior art date
Application number
NL1024831A
Other languages
English (en)
Other versions
NL1024831C2 (nl
Inventor
Rory F Finn
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of NL1024831A1 publication Critical patent/NL1024831A1/nl
Application granted granted Critical
Publication of NL1024831C2 publication Critical patent/NL1024831C2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NL1024831A 2002-11-20 2003-11-20 N-terminaal monogepegyleerde conjugaten van humaan groeihormoon en werkwijze voor de bereiding daarvan. NL1024831C2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42782302P 2002-11-20 2002-11-20
US42782302 2002-11-20

Publications (2)

Publication Number Publication Date
NL1024831A1 true NL1024831A1 (nl) 2004-05-26
NL1024831C2 NL1024831C2 (nl) 2005-04-28

Family

ID=32825103

Family Applications (3)

Application Number Title Priority Date Filing Date
NL1024831A NL1024831C2 (nl) 2002-11-20 2003-11-20 N-terminaal monogepegyleerde conjugaten van humaan groeihormoon en werkwijze voor de bereiding daarvan.
NL1028837A NL1028837C2 (nl) 2002-11-20 2005-04-21 N-terminaal monogepegyleerde conjugaten van humaan groeihormoon en werkwijze voor de bereiding daarvan.
NL1032282A NL1032282C2 (nl) 2002-11-20 2006-08-07 N-terminaal monogepegyleerde conjugaten van humaan groeihormoon en werkwijze voor de bereiding daarvan.

Family Applications After (2)

Application Number Title Priority Date Filing Date
NL1028837A NL1028837C2 (nl) 2002-11-20 2005-04-21 N-terminaal monogepegyleerde conjugaten van humaan groeihormoon en werkwijze voor de bereiding daarvan.
NL1032282A NL1032282C2 (nl) 2002-11-20 2006-08-07 N-terminaal monogepegyleerde conjugaten van humaan groeihormoon en werkwijze voor de bereiding daarvan.

Country Status (9)

Country Link
US (1) US20040127417A1 (nl)
AR (1) AR042103A1 (nl)
GT (1) GT200300250A (nl)
NL (3) NL1024831C2 (nl)
PA (1) PA8588901A1 (nl)
PE (1) PE20040797A1 (nl)
SV (1) SV2004001674A (nl)
TW (1) TWI281864B (nl)
UY (1) UY28085A1 (nl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
BR0314172A (pt) 2002-09-09 2005-07-26 Nektar Therapeutics Al Corp Polìmero solúvel em água, composição, forma de hidrato ou acetal, composto,composição, usos do composto e do conjugado, e, processo para preparar o conjugado
CA2498319A1 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
WO2004060300A2 (en) * 2002-12-26 2004-07-22 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
BR0317742A (pt) * 2002-12-26 2005-11-22 Mountain View Pharmaceuticals Conjugados poliméricos de interferon-beta com potência biológica aumentada
US20070105770A1 (en) * 2004-01-21 2007-05-10 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
BRPI0507436A (pt) * 2004-02-09 2007-07-03 Pharmacia Corp conjugados antagonistas de receptor do hormÈnio do crescimento humano quimicamente modificados
US20080182783A1 (en) * 2004-10-18 2008-07-31 Novo Nordisk A/S Growth Hormone Conjugates
WO2006042847A2 (en) * 2004-10-18 2006-04-27 Novo Nordisk A/S Method for the preparation of oxime, thiazolidine, dithiane, dithiolane or hydrazone linked analogues of growth hormone
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
EP1861125A2 (en) * 2005-03-23 2007-12-05 Nektar Therapeutics Al, Corporation Conjugates of an hgh moiety and peg derivatives
AU2006286486A1 (en) * 2005-08-30 2007-03-08 Novo Nordisk Health Care Ag Liquid formulations of pegylated growth hormone
WO2007097934A2 (en) * 2006-02-17 2007-08-30 Elusys Therapeutics, Inc. Methods and compositions for using erythrocytes as carriers for delivery of drugs
EP2040757A2 (en) * 2006-07-07 2009-04-01 Novo Nordisk Health Care AG New protein conjugates and methods for their preparation
WO2008051383A2 (en) * 2006-10-19 2008-05-02 Amgen Inc. Use of alcohol co-solvents to improve pegylation reaction yields
EP2157432A1 (en) * 2008-08-15 2010-02-24 Qiagen GmbH Method for analysing a complex sample by mass spectrometry
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
EP3355384A1 (en) * 2017-01-31 2018-08-01 Universite De Liege Flexible thin-films for battery electrodes
CN114539384A (zh) * 2020-11-19 2022-05-27 江苏众红生物工程创药研究院有限公司 聚乙二醇化长效生长激素及其制备方法和医药应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4342832A (en) * 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US5618697A (en) * 1982-12-10 1997-04-08 Novo Nordisk A/S Process for preparing a desired protein
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
ATE135370T1 (de) * 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
JP3051145B2 (ja) * 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
DE122006000003I1 (de) * 1995-09-21 2006-05-04 Genentech Inc Varianten des Menschlichen Wachstumshormons
JP2002534119A (ja) * 1999-01-14 2002-10-15 ボルダー バイオテクノロジー， インコーポレイテッド 自由システイン残基を有するタンパク質の生産方法
SE9904502D0 (sv) * 1999-12-09 1999-12-09 Pharmacia & Upjohn Ab Production of peptides

Also Published As

Publication number Publication date
PA8588901A1 (es) 2005-02-04
TW200418878A (en) 2004-10-01
NL1028837A1 (nl) 2005-08-30
US20040127417A1 (en) 2004-07-01
NL1028837C2 (nl) 2006-08-14
GT200300250A (es) 2004-08-18
UY28085A1 (es) 2004-07-30
SV2004001674A (es) 2004-05-17
PE20040797A1 (es) 2004-12-10
NL1032282C2 (nl) 2007-03-09
AR042103A1 (es) 2005-06-08
TWI281864B (en) 2007-06-01
NL1032282A1 (nl) 2006-11-07
NL1024831C2 (nl) 2005-04-28

Similar Documents

Publication Publication Date Title
NL1028837A1 (nl) N-terminaal monogepegyleerde conjugaten van humaan groeihormoon en werkwijze voor de bereiding daarvan.
NL1029828A1 (nl) Conjugaten van glycerol-vertakt polyethyleenglycol en menselijk groeihormoon, werkwijzen voor de bereiding daarvan en werkwijzen voor gebruik daarvan.
WO2005074546A3 (en) Modified human growth hormone polypeptides and their uses
HK1195512A1 (zh) 多糖-蛋白軛合物疫苗
WO2006069220A3 (en) Modified human growth hormone
PL373886A1 (en) Neutralizing human anti-igfr antibody
ZA200507067B (en) Antibodies against human IL-21 receptor and uses therefor
PL2272873T3 (pl) Przeciwciała przeciw receptorowi insulinopodobnego czynnika wzrostu I i ich zastosowania
HUS1300015I1 (hu) Humán IL-1béta elleni antitestek
IL207028A0 (en) Pharmaceutical nati-tnf-alpha antibody formulation
IL162031A0 (en) Chemically-modified human growth hormone conjugates
EP1676512A3 (en) Skin treatment articles and methods
MXPA01009645A (es) Anticuerpos humanos que unen il-12 humana y metodo para su produccion.
MXPA03008775A (es) Productos y metodos para mejorar la higiene dental animal.
AU2003299747A1 (en) Tumor killing/tumor regression using cxcr4 antagonists
IL174479A (en) The derivatives of myastrin, pharmaceutical preparations containing them and their uses
AU2003304235A1 (en) Chemically-modified human growth hormone conjugates
IL160998A0 (en) Human tissue factor antibodies
AU7676300A (en) Human anti-adipocyte monoclonal antibodies and their use
ZA200606224B (en) Modified human growth hormone polypeptides and their uses
AU2003236156A1 (en) Pharmaceutical compositions used for immune disease treatment and improvement
HRP20050142A2 (en) Steroid conjugates, preparation thereof and the use thereof
AU2003292805A1 (en) Animal excrement treatment material and process for producing the same
EG24959A (en) Indoles useful in the treatment of androgenreceptor related diseases.
HUP0402334A3 (en) Modified human growth hormone

Legal Events

Date Code Title Description
AD1A A request for search or an international type search has been filed
RD2N Patents in respect of which a decision has been taken or a report has been made (novelty report)

Effective date: 20041221

PD2B A search report has been drawn up
VD1 Lapsed due to non-payment of the annual fee

Effective date: 20090601